Repligen’s Promising Potential in 2011

Repligen’s Promising Potential in 2011

Seeking Alpha | December 24, 2010 | By Patrick Crutcher

Repligen Corporation (RGEN) is another attractive biotech that has revenues, cash and pending data in early 2011. With pending Phase 2 and Phase 3 data, Repligen seems set for a transformative 2011. Specifically, it has two important clinical catalysts in Q1 2011: Phase 3 data for RG1068 (pancreatic imaging agent) and Phase 2b data for its bipolar drug (RG2417). Both of these catalysts have the potential to take RGEN to new levels in 2011.

Click HERE or on the image below to read more…

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: